Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey

Clemente Ponzetti1 Group Policlinic Monza, Alessandria, National Scientific Associazione Nazionale dei Medici delle Direzioni Ospedaliere (National Association of Hospital Physicians), Bologna, Italy

Monica Canciani2 Studio EmmEffe S.r.l, Milan, Italy

Massimo Farina2 Studio EmmEffe S.r.l, Milan, ItalyCorrespondence[email protected]

Sara Era3 Roche S.p.a., Monza, Italy

Stefan Walzer4 MArS Market Access and Pricing Strategy GmbH, Weil am Rhein, Loerrach, Germany;5 Health Care Management, State University Baden-Wuerttemberg, Loerrach, Germany

References

European Medicine AgencyTrastuzumab (Herceptin). Summary of Product CharacteristicsEMA2014
Google Scholar
CardosoFCostaANortonLESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)Ann Oncol2014251871188825234545
PubMed Web of Science ®Google Scholar
CardosoFCostaANortonLESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)Breast201423489502 Available from: http://dx.doi.org/10.1016/j.breast.2014.08.009Accessed February 9, 201625244983
PubMed Web of Science ®Google Scholar
MastroianniCMViscomiCCenitiSPreferences of patients with advanced colorectal cancer for treatment with oral or intravenous chemotherapyPatient20081318118722272925
PubMedGoogle Scholar
European Medicine AgencyRituximab (Mabthera). Summary of Product CharacteristicsEMA2015
Google Scholar
RuleSCollinsGPSamantaKSubcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United KingdomJ Med Econ201417745946824720836
PubMedGoogle Scholar
FarinaMCancianiMPonzettiCThe role of subcutaneous formulations of biologics in the optimization processes of care in oncology and hematologyFrammenti Educational2014 Suppl 32 anno 8
Google Scholar

Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date